Tuesday, May 17, 2011

Novel two-drug combination cures young patient with extensively drug-resistant tuberculosis


The combination of meropenem (above structure)  with clavulanate (right structure-potassium salt)  has high antimycobacterial activity in vitro against extensively drug-resistant Mycobacterium tuberculosis strains. Researchers report the successful use of this combination in association with linezolid (below structure)  in the management of an advanced extensively drug-resistant tuberculosis disease with complex second-line drug resistance in a 14-year-old teenager.







    2. http://www.einstein.yu.edu/uploadedFiles/PHD/2010%20Faculty%20Research%20Book.pdf
at

4 comments:

  1. Stephan B17 May, 2011

    Clavulanate? Isn't that celecoxib?

    ReplyDelete
  2. https://www.med-chemist.com17 May, 2011

    No Stephenm is is a beta lactam derivative (http://en.wikipedia.org/wiki/Clavulanic_acid), where as celecoxib is a benzenesulfonamide (NSAID-http://en.wikipedia.org/wiki/Celecoxib).

    ReplyDelete
  3. Stephan B18 May, 2011

    On the screen I see a beta-lactam, a sulfonamide and a morpholine. The second image is even called celecoxib :)

    ReplyDelete
  4. https://www.med-chemist.com18 May, 2011

    Hello Steve,

    Thanks for noticing the mistake. You are right, the structure was that of celecoxib and now I have corrected the structure. Once again thanks for pointing out the mistake.

    ReplyDelete